<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082586</url>
  </required_header>
  <id_info>
    <org_study_id>SGH201705</org_study_id>
    <nct_id>NCT03082586</nct_id>
  </id_info>
  <brief_title>Radiation Dose Escalation in Esophageal Cancer</brief_title>
  <official_title>Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Cisplatin and Paclitaxel in Patients With Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to find the maximum tolerable dose of radiation that can be
      delivered combined with chemotherapy (DDP &amp; Paclitaxel) in patients with inoperable or
      medically unresectable esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RTOG 8501 has established concurrent radiochemotherapy as the standard of care for cancer
      of the esophagus.However, locoregional remain problematic, with 25% of patients having
      persistence and 20% relapse of locoregional disease following the combined modality approach.
      New regimen is urgently needed for improving localregional control and survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2016</start_date>
  <completion_date type="Actual">February 20, 2018</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>1 year</time_frame>
    <description>Maximum Tolerated Dose is defined as CTCAE 4 grade 3 acute radiation-related toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Local Failure</measure>
    <time_frame>2 years</time_frame>
    <description>Local control will be assessed radiographically using endoscopy with biopsy and a positron emission computed tomography-CT scan.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>radiochemotherapy 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 57.2 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 64.4 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 71.6 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 78.8 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 86 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 93.2 Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 1</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 1</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 2</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 2</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 3</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 3</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 4</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 4</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 5</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
    <arm_group_label>radiochemotherapy 5</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 6</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 6</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed primary squamous cell carcinoma of the esophagus

          2. Age 1 8-75.

          3. Patients must be deemed unresectable disease or patient is not deemed operable due to
             medical reasons.

          4. Patients with distant metastasis and life expectancy &gt;/= 3 months are eligible.

          5. Zubrod performance status 0 to 2

          6. No prior radiation to the thorax that would overlap with the current treatment field.

          7. Patients with nodal involvement are eligible

          8. Adequate bone marrow, renal and hepatic functions as assessed by the following:
             Hemoglobin &gt;/= 10.0 g/dl, Platelet count &gt;/= 1 00,000/mm^3,absolute granulocyte count
             (AGC) ≥2 × 10^9 cells/L,bilirubin and Aspartate transaminase ≤1.5 ×upper limit of
             normal (ULN), Creatinine &lt;/=1 .5 times ULN.

          9. A signed informed consent must be obtained prior to therapy. 1 0. Induction
             chemotherapy is allowed.

        Exclusion Criteria:

          1. The presence of a fistula.

          2. Prior radiotherapy that would overlap the radiation fields.

          3. gastroesophageal junction cancer.

          4. Uncontrolled concurrent illness including, but not limited to: Chronic Obstructive
             Pulmonary Disease(COPD) exacerbation or other respiratory illness, serious
             uncontrolled infection, symptomatic congestive heart failure (CHF),unstable angina
             pectoris, uncontrolled hypertension,or psychiatric illness/social situations that
             would limit compliance with the study requirements.

          5. Known hypersensitivity to paclitaxel.

          6. Any other condition or circumstance that would, in the opinion of the Investigator,
             make the patient unsuitable for participation in the study.

          7. Acquired Immune Deficiency Syndrome.

          8. Conditions precluding medical follow-up and protocol compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingfeng Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the ethic committee of shanghai genernal hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Ethic Committee of Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999 May 5;281(17):1623-7.</citation>
    <PMID>10235156</PMID>
  </results_reference>
  <results_reference>
    <citation>Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992 Jun 11;326(24):1593-8.</citation>
    <PMID>1584260</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chen tingfeng</investigator_full_name>
    <investigator_title>Director,department of radiation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

